FDA Grants Breakthrough Designation to AI Radiology Report Tool

What Happened

The U.S. Food and Drug Administration has granted Breakthrough Device Designation to First Read, an artificial intelligence system developed by Aidoc that is designed to draft radiology reports autonomously. The designation, announced this week, places First Read in a regulatory fast-track program reserved for devices that provide more effective diagnosis or treatment of serious conditions and where no approved alternatives currently exist.

What the Designation Means

FDA Breakthrough Device Designation is a formal program that enables more frequent and interactive communication between device developers and the FDA during the review process. It does not constitute approval or clearance for commercial use. Rather, it is intended to expedite development and review timelines for technologies that address unmet medical needs. Receiving the designation signals that the FDA has determined First Read meets the program's threshold criteria and that the agency will prioritize its review once a formal submission is filed.

The designation applies specifically to First Read's function of generating draft radiology reports, a step in clinical workflow that currently requires a licensed radiologist to compose findings from scratch before a secondary review. Aidoc positions the tool as designed to reduce the time radiologists spend on documentation, allowing them to focus on interpretation and clinical decision-making.

About Aidoc and First Read

Aidoc is a medical AI company whose existing cleared products are used across hospital systems in the United States and internationally. The company's platform is already deployed in areas including detection of conditions such as pulmonary embolism, intracranial hemorrhage, and aortic dissection, where its software flags urgent findings for radiologist review. First Read represents an extension of Aidoc's product line from detection and triage into report generation, a distinct and more complex workflow function.

First Read is described by the company as using AI to produce a structured draft report based on imaging data. Radiologists would then review, edit, and sign off on the AI-generated document before it becomes part of the patient record. The system is not intended to replace radiologist sign-off under the current proposed workflow.

Industry Context

Radiology departments across the United States have faced persistent staffing pressures. According to data cited by industry groups in prior years, radiologist shortages and increasing imaging volumes have contributed to longer turnaround times for reports. AI tools aimed at reducing administrative and documentation burden have attracted significant commercial and regulatory interest as a result.

The FDA's Breakthrough Device program, established under the 21st Century Cures Act of 2016, has seen a growing number of AI-based medical devices receive designation in recent years. The program covers software as a medical device, and the FDA has issued guidance documents specifically addressing AI and machine learning in clinical settings as the category has grown.

First Read would, if ultimately cleared or approved, enter a market that currently includes other AI-assisted documentation tools across medicine, though autonomous radiology report drafting at this level of regulatory engagement represents a distinct category within the radiology AI segment.

What It Means in Practice

Hospitals and radiology practices that are Aidoc customers will be watching the regulatory pathway for First Read closely. The Breakthrough Device Designation does not set a fixed timeline for when a final submission to the FDA must be made or when a decision would follow. Under the program's structure, Aidoc and the FDA will engage in ongoing dialogue about study design, evidence requirements, and submission format.

Radiologists would remain responsible for reviewing and approving any report produced by the system before it enters the clinical record, according to the workflow Aidoc has described for the product.

Aidoc is expected to continue discussions with the FDA under the Breakthrough Device program as it works toward a formal premarket submission for First Read.